Recent News

• 09.03.2025 - Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)
• 09.03.2025 - Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)
• 09.02.2025 - Outlook Therapeutics Requests Type A Meeting with FDA
• 09.02.2025 - Outlook Therapeutics Requests Type A Meeting with FDA
• 08.28.2025 - Outlook Therapeutics Corporate Update Conference Call
• 08.28.2025 - Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD
• 08.28.2025 - Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD
• 08.14.2025 - Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update
• 08.14.2025 - Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update
• 07.24.2025 - Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase

Recent Filings

• 09.02.2025 - 8-K Current report
• 09.02.2025 - EX-99.1 EX-99.1
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.14.2025 - EX-99.1 EX-99.1
• 08.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.14.2025 - 8-K Current report
• 07.31.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors